Literature DB >> 11859114

Expression of thrombospondin in TGFbeta-treated APCs and its relevance to their immune deviation-promoting properties.

Sharmila Masli1, Bruce Turpie, Karl H Hecker, J Wayne Streilein.   

Abstract

APCs deployed within iris/ciliary body are responsible for promoting anterior chamber-associated immune deviation following injection of Ag into the eye. TGFbeta-2, a constituent of the ocular microenvironment, converts conventional APCs that are pulsed with Ag into cells that induce immune deviation when injected into naive mice. TGFbeta-2-treated APCs under-express IL-12 and CD40, and over-express active TGFbeta. We have examined transcriptional changes within macrophage hybridoma no. 59, which promotes Th1 cell differentiation, and TGFbeta-2-treated no. 59 as well as macrophage hybridoma no. 63, both of which induce immune deviation similar to anterior chamber-associated immune deviation. Immune deviation-inducing hybridomas up-regulated expression of thrombospondin, TGFbeta, IFN-alpha and beta, murine macrophage elastase, and macrophage-inflammatory protein-2 genes, while down-regulating expression of the genes for NF-kappaB and CD40. Based on the known properties of these gene products, a model is proposed in which these gene products, alone and through interacting signaling pathways, confer upon conventional APCs the capacity to create and surround themselves with an immunomodulatory microenvironment. The model proposes that the pleiotropic effects of thrombospondin are primarily responsible for creating this microenvironment that is stabile, rich in active TGFbeta and IFN-alpha and beta, deficient in IL-12, and chemoattractant via macrophage-inflammatory protein-2 for NK T cells. It is further proposed that presentation of Ag to T cells in this microenvironment leads to their differentiation into regulatory cells that suppress Th1 cell-dependent immunogenic inflammation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11859114     DOI: 10.4049/jimmunol.168.5.2264

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  21 in total

1.  Ocular immune privilege in the year 2010: ocular immune privilege and uveitis.

Authors:  Andrew W Taylor; Henry J Kaplan
Journal:  Ocul Immunol Inflamm       Date:  2010-12       Impact factor: 3.070

Review 2.  Negative regulators that mediate ocular immune privilege.

Authors:  Andrew W Taylor; Tat Fong Ng
Journal:  J Leukoc Biol       Date:  2018-02-12       Impact factor: 4.962

3.  Increased IkappaB alpha expression is essential for the tolerogenic property of TGF-beta-exposed APCs.

Authors:  Paiman Ghafoori; Takeru Yoshimura; Bruce Turpie; Sharmila Masli
Journal:  FASEB J       Date:  2009-02-23       Impact factor: 5.191

Review 4.  Matricellular protein thrombospondins: influence on ocular angiogenesis, wound healing and immuneregulation.

Authors:  Sharmila Masli; Nader Sheibani; Claus Cursiefen; James Zieske
Journal:  Curr Eye Res       Date:  2014-02-21       Impact factor: 2.424

Review 5.  The spleen in local and systemic regulation of immunity.

Authors:  Vincenzo Bronte; Mikael J Pittet
Journal:  Immunity       Date:  2013-11-14       Impact factor: 31.745

Review 6.  Tolerogenic antigen-presenting cells: regulation of the immune response by TGF-beta-treated antigen-presenting cells.

Authors:  Michele M Kosiewicz; Pascale Alard
Journal:  Immunol Res       Date:  2004       Impact factor: 2.829

7.  Anti-inflammatory effects of tumour necrosis factor (TNF)-alpha are mediated via TNF-R2 (p75) in tolerogenic transforming growth factor-beta-treated antigen-presenting cells.

Authors:  Sharmila Masli; Bruce Turpie
Journal:  Immunology       Date:  2009-05       Impact factor: 7.397

8.  Ocular immune privilege.

Authors:  A W Taylor
Journal:  Eye (Lond)       Date:  2009-01-09       Impact factor: 3.775

9.  Thrombospondin-1-dependent immune regulation by transforming growth factor-β2-exposed antigen-presenting cells.

Authors:  Fayaz Ahmad Mir; Laura Contreras-Ruiz; Sharmila Masli
Journal:  Immunology       Date:  2015-10-12       Impact factor: 7.397

10.  FcγRI is required for TGFβ2-treated macrophage-induced tolerance.

Authors:  Z Gu; A Y Chhabra; P Alard; D R Warner; M M Kosiewicz
Journal:  Immunobiology       Date:  2013-04-12       Impact factor: 3.144

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.